Fig. 5

Steady-state pre-dose crenezumab concentration and Aβ(1–42) change from baseline in CSF at week 69. Data shown are from the phase II ABBY and BLAZE studies for patients enrolled in 300 mg q2w SC or 15 mg/kg q4w IV cohorts. Abbreviations: Aβ beta-amyloid, CSF cerebrospinal fluid, IV intravenous, q2w every 2 weeks, q4w every 4 weeks, SC subcutaneous